Business
Novus Showcased by Cannabis Business Times
Novus Showcased by Cannabis Business Times.
About this update from Novus Acquisition & Development Corp.
[{"type":"text","content":"Highlighting Novus' U.S. And Canadian Business Model MIAMI, FL / ACCESSWIRE / November 6, 2017 / Novus Acquisition and Development, Corp. (OTC PINK: NDEV), through its wholly-owned subsidiary, WCIG Insurance Services, Inc., is a diversified insurance entity in health, liability, annuity and accident and the nation's first carrier/aggregator offering a cannabis health plan. NDEV today announced a featured cover article in Cannabis Business Times publication.The article can be read here: http://bit.ly/2h1HXIL.Cannabis Business Times (CBT) is a leading cannabis industry publication that focuses accelerated success of the legal cannabis cultivators, manufacturers, dispensaries, and patient advocacy. CBT provides actionable intelligence in all aspects of the industry, from legislation, regulation, and compliance news to analysis of industry trends, as well as expert advice on cultivation, marketing, financial topics, legal issues, and more.CBT focuses strictly on the business of legal cannabis for medical and recreational use and aims to provide timely information - through its website, e-newsletter, mobile app, print magazine and annual cultivation conference - to help the reader make timely, informed decisions to help them run their businesses better and more profitably.About NovusNovus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contain...